10:24 AM EDT, 10/13/2026 (MT Newswires) -- The UK's Medicines and Healthcare products Regulatory Agency approved Eli Lilly's (LLY.SW, LLY.F) Onswik, or insulin efsitora alfa, for adults with type 2 diabetes mellitus. The medicine company's once-weekly, long-acting basal insulin could cut the number of injections needed for type 2 diabetes to 52 a year from up to 365, according to a Tuesday notice. The approval followed a "rigorous" assessment of the available evidence. The regulator said it will keep monitoring the medicine's safety closely through its established surveillance systems.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.